ResearcherUniversity of North Carolina at CharlotteActive in the last 2 years
Dakota W. Goad
Matched on OpenAlex author ID A5087348211. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper
Papers 3
- Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stomatitis virus. First author DOI 10.1016/j.omton.2025.201089↗
- Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells. Co-author DOI 10.1128/jvi.01005-23↗
- Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Co-author DOI 10.1016/j.omto.2021.11.019↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Valery Z. Grdzelishvili · 3 shared papers, 2022–2025 · strength 0.77
- Paper Fostamatinib (R788), a spleen tyrosine kinase inhibitor, sensitizes pancreatic cancer cells to oncolytic vesicular stom… DOI 10.1016/j.omton.2025.201089↗
- Paper Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells. DOI 10.1128/jvi.01005-23↗
- Paper Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis … DOI 10.1016/j.omto.2021.11.019↗
- Cassandra Catacalos-Goad · 1 shared paper, 2025 · strength 0.28
- Christian Bressy · 1 shared paper, 2022 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.